Brief: PharmaCyte Biotech Receives CE Mark For Licensed COVID-19 Molecular Tests
29/07/2020 14:38
July 29 (Reuters) - PharmaCyte Biotech Inc PMCB.PK :
* PHARMACYTE BIOTECH RECEIVES CE MARK FOR LICENSED COVID-19
MOLECULAR TESTS
Source text for Eikon: ID:nBw4sKqRHa
Further company coverage: PMCB.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pharmacyte Biotech
See all newsBrief: Pharmacyte Biotech Inc - Increases Stake In Tnf Pharmaceuticals By $3 Million
Brief: PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease
Brief: Pharmacyte Biotech Acquires $5 Million Stake In Emerging Women’S Health Innovator Femasys
Brief: Femasys Inc. Secures Additional Financing With Strategic Investment From Investors Led By Pharmacyte Biotech
Brief: Pharmacyte Biotech Announces Final Results Of Tender Offer